Publication in refereed journal
香港中文大学研究人员 ( 现职)
| 莫树锦教授 (肿瘤学系) |
全文
| 数位物件识别号 (DOI) http://dx.doi.org/10.2217/fon.14.22 |
引用次数
Web of Sciencehttp://aims.cuhk.edu.hk/converis/portal/Publication/0WOS source URL
Scopushttp://aims.cuhk.edu.hk/converis/portal/Publication/6Scopus source URL
其它资讯
摘要Dacomitinib (PF-http://aims.cuhk.edu.hk/converis/portal/Publication/0http://aims.cuhk.edu.hk/converis/portal/Publication/02998http://aims.cuhk.edu.hk/converis/portal/Publication/04) is a second-generation irreversible HER tyrosine kinase inhibitor (TKI). In preclinical studies, dacomitinib has demonstrated anti-tumor activity in lung cancer cell lines with sensitive and resistant EGFR mutations (including the T79http://aims.cuhk.edu.hk/converis/portal/Publication/0 mutation). Safety and well tolerability of dacomitinib were demonstrated in Phase I studies with stomatitis, diarrhea and skin toxicities being the dose-limiting toxicities. The maximum tolerated dose was established to be 45 mg/day. In Phase II and III studies, dacomitinib has shown clinical activity in both HER tyrosine kinase-naive and HER tyrosine kinase failure settings. Further clinical trials are underway to evaluate the efficacy of dacomitinib in non-small-cell lung cancer. ? 2http://aims.cuhk.edu.hk/converis/portal/Publication/014 Future Medicine Ltd.
着者Mok T., Lee K., Tang M., Leung L.
期刊名称Future Oncology
出版年份2http://aims.cuhk.edu.hk/converis/portal/Publication/014
月份1
日期1
卷号1http://aims.cuhk.edu.hk/converis/portal/Publication/0
期次5
出版社Future Medicine Ltd.
出版地United Kingdom
页次813 - 822
国际标準期刊号1479-http://aims.cuhk.edu.hk/converis/portal/Publication/6http://aims.cuhk.edu.hk/converis/portal/Publication/694
电子国际标準期刊号1744-83http://aims.cuhk.edu.hk/converis/portal/Publication/01
语言英式英语
关键词afatinib, carcinoma, EGF, erlotinib, gefitinib, non-small-cell lung, protein kinase inhibitors, receptor
